Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5 studies found for:    rsv niaid | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
rsv niaid | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 1030s vaccine;   Biological: Placebo
2 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
3 Recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
4 Recruiting Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
5 Recruiting Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46cpΔM2-2 vaccine;   Biological: Placebo

Study has passed its completion date and status has not been verified in more than two years.